Organigram Strives For 'High Potency Cannabinoid' With $6M Phylos Investment

Zinger Key Points
  • Organigram invests $2.75 million to Phylos, boosting their total investment to $6 million.
  • Milestone-driven funding enhances development of rare cannabinoid cultivars, aiming to revolutionize the cannabis market.

OrganiGram Holdings Inc OGI, a Canadian cannabis operator producer, has increased its investment in Phylos Bioscience Inc., a U.S.-based cannabis genetics company.

Following the achievement of a crucial milestone under their May 2023 loan agreement, Organigram has closed the second tranche, advancing $2.75 million to Phylos. This brings the total senior secured convertible loans to $6 million. 

"We have always strived to be at the forefront of innovation through our commitment to scientific excellence and rigorous research. Our investment in Phylos was driven by that commitment, and we are thrilled with the progress we have made and the benefits we are reaping from this strategic investment," says Borna Zlamalik, senior vice president of R&D and innovation at Organigram. 

"To further expand and capitalize on this investment in Phylos, we are preparing the development of additional breeding programs which aim to deliver a suite of high potency minor cannabinoid flower to complement the THCV flower, with a focus on key rare cannabinoids such as CBG, CBC, CBDV and THCP," he added.

Phylos creates cost-effective cannabis varietals. This includes a range of THCV cultivars with targeted potencies and specific aroma profiles.

In August, Organigram introduced its first THCV product lineup under its SHRED and Trailblazer brands, utilizing Phylos’ technology. The convertible loans from Organigram to Phylos will accrue interest and are convertible into common share equity of Phylos under specific conditions, including U.S. federal cannabis legalization.

Loan Agreement Details

The loan agreement stipulates additional funding of up to $2 million by May 2025, depending on milestone completion. The convertible loans, accruing interest at U.S. Prime + 3.5%, can be converted into Phylos equity under certain conditions​​.

OGI Price Action
OGI's shares were trading 1.69% higher at $1.27 per share at the time of this writing around 1:30 p.m. EST Tuesday.

Related News

Image created with generative AI tools.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechCannabisFinancingPress ReleasesCanadian cannabisCanadian cannabis companiesOrganigram Holdings Inc.Phylos Bioscience
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis is evolving – don’t get left behind!

Curious about what’s next for the industry and how to leverage California’s unique market?

Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!

Get your tickets now to secure your spot and avoid last-minute price hikes.